Lv1
60 积分 2023-08-06 加入
Izalontamab brengitecan, an EGFR and HER3 bispecificantibody-drug conjugate, versus chemotherapy in heavilypretreated recurrent or metastatic nasopharyngealcarcinoma: a multicentre,randomised,open-label, phase 3study in China
2天前
已完结
Reovirus Therapy of Tumors with Activated Ras Pathway
26天前
已关闭
The next generation of immunotherapies for lung cancers
30天前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
30天前
已完结
Oncolytic virus VG161 in refractory hepatocellular carcinoma
1个月前
已完结
Advances in antibody-based therapy in oncology
2个月前
已完结
皖公网安备34019202002308
